Company intelligence / Profile preview

YewSavin

Fort Collins, Colorado, United Statesyewsavin.com ↗

Ownership: Private
Employees: ~10
Development stage: Other

Overview

YewSavin has developed a proprietary AI/SAR-based platform to identify plant-derived small molecules for oral treatment of hemophilia. Their lead program demonstrated significant improvement in clotting time in animal models compared to standard therapy. The approach aims to balance hemostasis and thrombosis with non-immunogenic oral agents.

Therapeutic areas: Hematology
Modalities: Small moleculePlant-derived compounds
Industry: Biotech

Partnerships

KBI Biopharma is referenced as a powering partner/platform collaborator.

Beyond the preview

Go deeper on YewSavin.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on YewSavin.

Explore the full profile